#STRATA ONCOLOGY TRIAL#

9, 2021 /PRNewswire/ - CB Insights today named Strata Oncology to its third annual Digital Health 150, which showcases the 150 most promising private digital health companies in the world. The company combines molecular profiling, real-world data, and large-scale clinical trials to identify and deliver optimal treatments for patients with cancer. is a precision oncology company dedicated to delivering the best possible treatment for each patient with cancer. StrataMRD is performed at the Strata Oncology Ann Arbor, MI CAP-accredited and CLIA-certified laboratory. The ultra-sensitive, individualized blood test leverages multiplexed PCR amplicon-based NGS of blood-based ctDNA to monitor for a personalized set of informative mutations. The investigational test is available through the Sentinel Trial. StrataMRD is a tumor-informed, personalized circulating tumor DNA (ctDNA) test to detect tumor recurrence and monitor treatment effectiveness for patients. Cancer that remains at low levels after initial treatment is also called micrometastatic. MRD can be detected using circulating tumor DNA (ctDNA), which consists of small pieces of tumor-derived DNA that are shed into the bloodstream. These remaining cells are called minimal residual disease (MRD) and often result in recurrence. However, very small numbers of cancer cells that are undetectable using standard techniques like imaging may remain in the body. The treatment plan for patients with early-stage cancer often entails surgery, chemotherapy or radiation (or some combination of these) given with the intent of curing the disease.

#STRATA ONCOLOGY TRIAL#

All molecular profiling in the Strata Sentinel trial will be performed at Strata Oncology's Ann Arbor, MI CAP-accredited and CLIA-certified laboratory and outcomes data will be collected for up to five years. If recurrence is detected, treating physicians may then use the comprehensive therapy selection profile information to guide treatment decisions, including enrollment in the Strata PATH™ clinical trial. Blood samples will be collected every 3 months and tested for the presence of ctDNA. Information and samples from participants will be collected during standard of care visits with their doctors. The Strata Sentinel trial will enroll approximately 100,000 patients with stage 1-3 solid tumors across 25 sites and is the largest trial of its kind to date. 'With that information, we can get patients who need their optimal precision therapy long before a full-on recurrence of metastatic disease, and we can spare those patients who really are cured from the toxicities and costs of unnecessary adjuvant treatment.' 'In the future we'll know very soon after initial treatment which early-stage cancer patients are or are not destined for recurrence,' said Rhodes. A key feature of StrataMRD is its 0.01% tumor content limit of detection, which is made possible by Strata's personalized approach of exhaustively searching the blood for specific mutations known to occur in each patient's tumor.

Strata oncology